celecoxib has been researched along with Osteosarcoma in 13 studies
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " EGFR and cyclooxygenase-2 (COX-2) were found overexpressed in osteosarcoma in previous reports, so here we tried to explore the anti-osteosarcoma effect of ZD6474 alone or combination with celecoxib, a COX-2 inhibitor." | 7.81 | ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. ( Chen, JM; Chen, S; Du, W; Huang, W; Liu, J; Liu, RY; Pan, C; Shen, J; Wu, J; Zhou, L; Zhou, Y; Zhu, X, 2015) |
| "The goal of this study was to determine the effect of celecoxib, a selective COX-2 inhibitor, on the growth inhibition of osteosarcoma and its potential anticancer mechanisms." | 7.81 | Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line. ( Fan, GT; Ren, K; Shi, X; Wu, SJ; Zhao, JN; Zhou, X, 2015) |
| "Celecoxib (Cel) is a COX-2-selective nonsteroidal anti-inflammatory drug and its antitumoral effect has been shown widely in a variety of cancers including OS cells in vitro." | 5.46 | The potential combinational effect of miR-34a with celecoxib in osteosarcoma. ( Chen, X; Huang, J; Liu, B; Peng, D; Shen, Y; Tao, H; Zhou, H, 2017) |
| " EGFR and cyclooxygenase-2 (COX-2) were found overexpressed in osteosarcoma in previous reports, so here we tried to explore the anti-osteosarcoma effect of ZD6474 alone or combination with celecoxib, a COX-2 inhibitor." | 3.81 | ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. ( Chen, JM; Chen, S; Du, W; Huang, W; Liu, J; Liu, RY; Pan, C; Shen, J; Wu, J; Zhou, L; Zhou, Y; Zhu, X, 2015) |
| "The goal of this study was to determine the effect of celecoxib, a selective COX-2 inhibitor, on the growth inhibition of osteosarcoma and its potential anticancer mechanisms." | 3.81 | Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line. ( Fan, GT; Ren, K; Shi, X; Wu, SJ; Zhao, JN; Zhou, X, 2015) |
| "When treatment was started prior to tumor cell implantation, doxycycline inhibited osteosarcoma tumor growth alone and in combination with celecoxib (30% and 33% reduction, respectively)." | 3.72 | Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. ( Cripe, TP; Dickens, DS, 2003) |
| "Celecoxib (Cel) is a COX-2-selective nonsteroidal anti-inflammatory drug and its antitumoral effect has been shown widely in a variety of cancers including OS cells in vitro." | 1.46 | The potential combinational effect of miR-34a with celecoxib in osteosarcoma. ( Chen, X; Huang, J; Liu, B; Peng, D; Shen, Y; Tao, H; Zhou, H, 2017) |
| "Osteosarcoma is the most common primary bone tumor, but the pathogenesis is not well understood." | 1.34 | Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells. ( Choe, M; Choi, EM; Ha, KS; Han, JA; Kim, H; Kim, JI; Kim, SR; Kim, SS; Kim, YM; Lee, EJ; Park, JH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Kast, RE | 1 |
| Chen, X | 1 |
| Peng, D | 1 |
| Shen, Y | 1 |
| Liu, B | 2 |
| Zhou, H | 1 |
| Tao, H | 1 |
| Huang, J | 1 |
| Zhou, P | 1 |
| Li, Y | 1 |
| Li, B | 1 |
| Zhang, M | 1 |
| Xu, C | 1 |
| Liu, F | 1 |
| Bian, L | 1 |
| Liu, Y | 1 |
| Yao, Y | 1 |
| Li, D | 1 |
| Krzyzankova, M | 1 |
| Chovanova, S | 1 |
| Chlapek, P | 1 |
| Radsetoulal, M | 1 |
| Neradil, J | 1 |
| Zitterbart, K | 1 |
| Sterba, J | 1 |
| Veselska, R | 1 |
| Liu, G | 1 |
| Yu, MY | 1 |
| Huang, X | 1 |
| Zhu, D | 1 |
| Cheng, S | 1 |
| Ma, R | 1 |
| Gu, G | 1 |
| Liu, J | 1 |
| Wu, J | 1 |
| Zhou, L | 1 |
| Pan, C | 1 |
| Zhou, Y | 1 |
| Du, W | 1 |
| Chen, JM | 1 |
| Zhu, X | 1 |
| Shen, J | 1 |
| Chen, S | 1 |
| Liu, RY | 1 |
| Huang, W | 1 |
| Zhou, X | 1 |
| Shi, X | 1 |
| Ren, K | 1 |
| Fan, GT | 1 |
| Wu, SJ | 1 |
| Zhao, JN | 1 |
| Dickens, DS | 1 |
| Cripe, TP | 1 |
| Takahashi, T | 1 |
| Ogawa, Y | 1 |
| Kobayashi, T | 1 |
| Sonobe, H | 1 |
| Seguchi, H | 1 |
| Tani, T | 1 |
| Yoshida, S | 1 |
| Tsai, YC | 1 |
| Wu, CT | 1 |
| Hong, RL | 1 |
| Masi, L | 1 |
| Recenti, R | 1 |
| Silvestri, S | 1 |
| Pinzani, P | 1 |
| Pepi, M | 1 |
| Paglierani, M | 1 |
| Brandi, ML | 1 |
| Franchi, A | 1 |
| Lee, EJ | 1 |
| Choi, EM | 1 |
| Kim, SR | 1 |
| Park, JH | 1 |
| Kim, H | 1 |
| Ha, KS | 1 |
| Kim, YM | 1 |
| Kim, SS | 1 |
| Choe, M | 1 |
| Kim, JI | 1 |
| Han, JA | 1 |
| Shi, ZL | 1 |
| Feng, J | 1 |
| Tao, HM | 1 |
1 review available for celecoxib and Osteosarcoma
| Article | Year |
|---|---|
The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Bone Neoplasms; Celecoxib; Humans; Osteo | 2023 |
12 other studies available for celecoxib and Osteosarcoma
| Article | Year |
|---|---|
The potential combinational effect of miR-34a with celecoxib in osteosarcoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2017 |
Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Carcinogenesis; C | 2018 |
LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Caffeic Acids; Celecoxib; Cell Differentiation; Cell Line, Tu | 2014 |
Synergistic effect of celecoxib in tumor necrosis factor‑related apoptosis‑inducing ligand treatment in osteosarcoma cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; bcl-2-Associated X Protein; Bone Neopla | 2014 |
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Celecoxib; Cell | 2015 |
Celecoxib inhibits cell growth and modulates the expression of matrix metalloproteinases in human osteosarcoma MG-63 cell line.
Topics: Apoptosis; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibit | 2015 |
Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Celecoxib; Cyclo | 2003 |
A combination of selective COX-2 inhibitors and hydrogen peroxide increase the reactive oxygen species formation in osteosarcoma cells after X-ray irradiation.
Topics: Celecoxib; Cell Line, Tumor; Culture Media; Cyclooxygenase Inhibitors; Dose-Response Relationship, D | 2004 |
Response of refractory osteosarcoma to thalidomide and celecoxib.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Celecoxib; Drug Resistance, Neoplasm | 2005 |
Expression of cyclooxygenase-2 in osteosarcoma of bone.
Topics: Apoptosis; Biopsy; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Humans; Immuno | 2007 |
Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells.
Topics: Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenase 2; Cy | 2007 |
Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; C | 2008 |